Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Rituxan Prescribers: Rheumatologists

Dipti Doshi, MD, Rheumatologist
HEALTHCARE PARTNERS MEDICAL GROUP
May 1, 2008
TRU-015 and SBI-087 both trubion's product both strong products with Different MOA , B cell depletion.
Analysis of: Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis (www.pipelinereview.com)
Drug therapies for RA include (NSAIDS), DMARDS, and, most recently, biologics. Biologics currently on the market for RA target immune messengers called cytokines, which promote the damaging inflammatory process, and include anti-tumor necrosis factor (TNF) drugs – infliximab , etanercept,adalimumab,...
Dipti Doshi, MD, Rheumatologist
HEALTHCARE PARTNERS MEDICAL GROUP
July 4, 2007
Phase 2 study showing that a 1mg treatment with Adlea(TM) effective for 12 week persistant pain in OA patients
Analysis of: Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee (www.pipelinereview.com)
Pharmacokinetic studies of Adlea showed that when it is locally administered to the site of pain, there appears to be limited systemic exposure. Its short duration of systemic exposure (hours) relative to the long duration of analgesia (12 weeks) resulting from a single treatment course of Adlea is...
Dipti Doshi, MD, Rheumatologist
HEALTHCARE PARTNERS MEDICAL GROUP
June 18, 2007
Roche's market share will go up .
Analysis of: New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis (pharmalive.com)
Very important new treatment emerging in field of rheumatoid arthritis along with other drugs in pipeline. IL-6 receptor blocker. New Mechanism of action. Has positive priliminary endpoint results at 24 week study for RA compared to DMARD therapy alone.
Dipti Doshi, MD, Rheumatologist
HEALTHCARE PARTNERS MEDICAL GROUP
May 28, 2007
SRV in non responders
Analysis of: "Triple Anti-HCV Drug Therapy for Nonresponders to Peginterferon/Ribavirin: Interferon Gamma (Actimmune) + Ribavirin + Pegasys or Infergen: A Pilot Study" (www.natap.org)
Very nice article. Although sample size seemed very less, avaialble results look very promising. Particularly in contrast of Leevy study. Only concern is of side-effects. Would make things clear on further study with the same drug

Page : 11 to 4 of 4

Analytics


Generated at 2009-01-09T13:00:20.343